Contraceptive Vaginal Rings

Bryna Harwood; Daniel R. Mishell Jr

doi:10.1055/s-2001-18646

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2001; 19(4): 381-390
DOI: 10.1055/s-2001-18646

Contraceptive Vaginal Rings

Bryna Harwood¹ , Daniel R. Mishell, Jr.²

¹Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
²Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California

Abstract

ABSTRACT

Contraceptive vaginal rings (CVRs) contain sex steroids that diffuse through a plastic polymer ring at a constant rate and are absorbed directly through the vaginal epithelium into the systemic circulation. This delivery system provides many advantages over oral contraceptives (OCs), including avoidance of the first-pass effect through the liver, constant serum steroid levels, longer duration of use, and greater bioavailability of the hormones. CVRs containing progestin only are designed for continuous use for 3 to 6 months. Those containing progesterone alone are indicated for use in women who are breastfeeding. Large clinical trials of progestin-containing CVRs demonstrated good efficacy and safety of the CVR, with continuation rates similar to that of OCs. CVRs containing a combination of estrogen and progestin are designed to be used for 1 to 12 months in a cyclic manner similar to OCs, with withdrawal bleeding in the fourth week of each cycle. In clinical trials these CVRs have typical use efficacies similar to OCs, with an acceptable pattern of bleeding.

KEYWORD

Contraception - sex steroid hormones - vaginal ring

Full Text

References

REFERENCES

1 Macht D. The absorption of drugs and poisons through the vagina. Journal of Pharmacology Path . 1918; 10 509
2 Dzuik P, Cook B. Passage of steroids through silicone rubber. Endocrinology . 1966; 78 208-211
3 Roumen F, Dieben T. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception . 1999; 59 59-62
4 Timmer C, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. Contraception . 1990; 42 629-642
5 Landgren B, Johannisson E, Masironi B, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Contraception . 1982; 26 567-585
6 Jackanicz T M. Levonorgestrel and estradiol release from an improved contraceptive vaginal ring. Contraception . 1981; 24 323-339
7 Mishell D R, Talas M, Parlow A, Moyer D L. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol . 1970; 107 100-107
8 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial I: contraceptive efficacy and side effects. Contraception . 1990; 41 105-124
9 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial IV: bleeding patterns. Contraception . 1990; 41 151-167
10 Ji G, Hong-zhu S, Gui-ying S, Li-yuan M. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring. Fertil Steril . 1986; 46 626-630
11 Bounds W, Szarewski A, Lowe D. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring. Eur J Obstet Gynecol Reprod Biol . 1993; 48 123-125
12 Diaz S, Jackanicz T, Herreros C. Fertility regulation in nursing women VIII: progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring. Contraception . 1985; 32 603-621
13 Chen J, Wu S, Shao W. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women. Contraception . 1998; 57 371-379
14 Sivin I, Diaz S, Croxatto H B. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD. Contraception . 1997; 55 225-232
15 Mishell D R, Moore D E, Roy S, Brenner P F, Page M A. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Am J Obstet Gynecol . 1978; 130 55-62
16 Sivin I, Mishell D R, Victor A. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings I: use effectiveness. Contraception . 1981; 24 341-358
17 Roy S, Krauss R M, Mishell D R, Casagrande J, Pike M C. The effect on lipids and lipoproteins of a contraceptive vaginal ring containing levonorgestrel and estradiol. Contraception . 1981; 24 429-449
18 Robertson D, Alvarez F, Sivin I. Lipoprotein patterns in women in Santo Domingo using a levonorgestrel/estradiol contraceptive ring. Contraception . 1981; 24 469-479
19 Ahren T, Lithell H, Victor A, Vessby B, Johansson E D. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring II: serum lipoproteins and apolipoproteins. Contraception . 1981; 24 451-467
20 Ahren T, Lithell H, Victor A, Vessby B, Johansson E D. Comparison of the metabolic effects of two hormonal contraceptive methods-an oral formulation and a vaginal ring I: carbohydrate metabolism and liver function. Contraception . 1981; 24 415-427
21 Ahren T, Victor A, Lithell H, Vessby B, Jackanicz T M, Johansson E D. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins. Contraception . 1983; 28 315-327
22 Adams M, Clarkson T, Koritnik D, Nash H A. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques. Fertil Steril . 1987; 47 1010-1018
23 Ballagh S A, Mishell D R, Jackanicz T M, Lacarra M, Eggena P. Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol. Contraception . 1994; 50 535-549
24 Ballagh S A, Mishell D R, Lacarra M, Shoupe D, Jackanicz T M, Eggena P. A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol. Contraception . 1994; 50 517-533
25 Weisberg E, Fraser I S, Lacarra M. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring. Contraception . 1999; 59 311-318
26 Weisberg E, Fraser I S, Mishell D R, Lacarra M, Darney P, Jackanicz T M. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol. Contraception . 1999; 59 305-310
27 Weisberg E, Fraser I S, Lacarra M, Mishell D R, Jackanicz T M. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring. Contraception . 1997; 56 233-239
28 Laurikka-Routti M, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry. Contraception . 1990; 42 111-120
29 Alvarez-Sanchez F. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles. Contraception . 1992; 46 387-398
30 Apter D, Cacciatore B, Stenman U, Alapiessa U, Assendorp R. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol. Contraception . 1990; 42 285-295
31 Olsson S-E, Odlind V. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol. Contraception . 1990; 42 563-572
32 Timmer C J, Mulders T M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet . 2000; 39 233-242
33 Mulders T M, Dieben T. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition. Fertil Steril . 2001; 75 865-870
34 Roumen F, Apter D, Mulders T M, Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol. Hum Reprod . 2001; 16 469-475
35 Fraser I S, Weisberg E, Minehan E, Johansson E D. A detailed analysis of menstrual blood loss in women using Norplant℗ and Nestorone℗ progestogen-only contraceptive implants or vaginal rings. Contraception . 2000; 61 241-251
36 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial II: expulsions and removals. Contraception . 1990; 41 125-141
37 Sivin I, Mishell D R, Victor A. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings II: subjective and objective measures of effects. Contraception . 1981; 24 359-376
38 Schwan A, Ahren T, Victor A. Effects of contraceptive vaginal ring treatment on vaginal bacteriology and cytology. Contraception . 1983; 28 341-347
39 Roy S, Wilkins J, Mishell D R. The effect of a contraceptive vaginal ring and oral contraceptives on the vaginal flora. Contraception . 1981; 24 481-491
40 Fraser I S, Lacarra M, Mishell D R. Vaginal epithelial surface appearances in women using vaginal rings for contraception. Contraception . 2000; 61 131-138
41 Faundes A, Hardy E, Reyes Q, Pastene L, Portes-Carrasco R. Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries. Contraception . 1981; 24 393-414
42 Fu H, Darroch J E, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect . 1999; 31 56-63